rc 3095 has been researched along with Experimental Mammary Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, RZ; Groot, K; Halmos, G; Pinski, J; Schally, AV; Shirahige, Y; Szepeshazi, K | 1 |
| Groot, K; Halmos, G; Horvath, JE; Lamharzi, N; Schally, AV; Szepeshazi, K | 1 |
| Groot, K; Halmos, G; Radulovic, S; Schally, AV; Szepeshazi, K | 1 |
3 other study(ies) available for rc 3095 and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
Topics: Animals; Antineoplastic Agents; Bombesin; Breast Neoplasms; Down-Regulation; ErbB Receptors; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Peptide Fragments; Transplantation, Heterologous; Tumor Cells, Cultured | 1994 |
A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.
Topics: Animals; Anticarcinogenic Agents; Bombesin; Cricetinae; ErbB Receptors; Female; Male; Mammary Neoplasms, Experimental; Mesocricetus; Mice; Mice, Nude; Peptide Fragments; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1997 |
Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Topics: Animals; Antineoplastic Agents; Bombesin; ErbB Receptors; Estrogens; Female; Gastrin-Releasing Peptide; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasms, Hormone-Dependent; Peptide Fragments; Peptides | 1992 |